Indication

Type 2 Diabetes Mellitus

Administration

SC Administration Administer SC to abdomen, thigh, or upper arm Administer once weekly, on the same day each week, at any time of the day, with or w... View More

Adult Dose

Type 2 Diabetes Mellitus Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus 0.25 mg SC... View More

Child Dose

<18 years: Safety and efficacy not established

Renal Dose

Renal impairment No dosage adjustment required

Contraindication

Personal or family history of MTC or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2) Known hypersensitivity to semaglutide or t... View More

Mode of Action

Glucagon-like peptide-1 (GLP-1) agonist Incretins, such as GLP-1, enhance glucose-dependent insulin secretion by pancreatic beta-cells, suppresses in... View More

Precaution

Based on findings in rats and mice, semaglutide may cause thyroid C-cell tumors including MTC, in humans as human relevance of semaglutide-induced roden... View More

Side Effect

>10% Nausea (15.8-20.3%) Documented symptomatic hypoglycemia, adjunctive therapy [≤70 mg/dL glucose threshold] (16.7-29.8%) Severe or symptomatic... View More

Pregnancy Category Note

Pregnancy Data are limited regarding use in pregnant women Based on animal reproduction studies, there may be potential risks to the fetus from expo... View More

Interaction

Coadministration with insulin secretagogues (eg, sulfonylureas) or insulin may increase the risk of hypoglycemia; consider a lower dose of the secretagogue or insulin to reduce risk of hypoglycemia in this setting Exercise caution when semaglutide is concomitantly administered with oral medications; semaglutide causes a delay of gastric emptying, thereby potentially impacting oral absorption of such medications